{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:54:29Z","timestamp":1792652069903,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000402","name":"Kay Kendall Leukaemia Fund","doi-asserted-by":"publisher","award":["KKL1443"],"award-info":[{"award-number":["KKL1443"]}],"id":[{"id":"10.13039\/501100000402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["Unit grants MC_UU_00016\/6 and MC_UU_00029\/6"],"award-info":[{"award-number":["Unit grants MC_UU_00016\/6 and MC_UU_00029\/6"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["Unit grants MC_UU_00016\/6 and MC_UU_00029\/6"],"award-info":[{"award-number":["Unit grants MC_UU_00016\/6 and MC_UU_00029\/6"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In <jats:italic>KMT2A<\/jats:italic>-rearranged acute lymphoblastic leukemia (ALL), an aggressive malignancy, oncogenic KMT2A-fusion proteins inappropriately recruit DOT1L to promote leukemogenesis, highlighting DOT1L as an attractive therapeutic target. Unfortunately, treatment with the first-in-class DOT1L inhibitor pinometostat eventually leads to non-responsiveness. To understand this we established acquired pinometostat resistance in pediatric KMT2A::AFF1<jats:sup><jats:italic>+<\/jats:italic><\/jats:sup> B-ALL cells. Interestingly, these cells became mostly independent of DOT1L-mediated H3K79 methylation, but still relied on the physical presence of DOT1L, HOXA9 and the KMT2A::AFF1 fusion. Moreover, these cells selectively lost the epigenetic regulation and expression of various KMT2A-fusion target genes such as <jats:italic>PROM1\/<\/jats:italic>CD133, while other KMT2A::AFF1 target genes, including <jats:italic>HOXA9<\/jats:italic> and <jats:italic>CDK6<\/jats:italic>\u00a0remained unaffected. Concomitantly, these pinometostat-resistant cells showed upregulation of several myeloid-associated genes, including <jats:italic>CD33<\/jats:italic> and <jats:italic>LILRB4\/CD85k.<\/jats:italic> Taken together, this model comprehensively shows the adaptive potential of <jats:italic>KMT2A<\/jats:italic>-rearranged ALL cells upon losing dependency on one of its main oncogenic properties.<\/jats:p>","DOI":"10.1186\/s40164-023-00445-8","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T12:02:19Z","timestamp":1695384139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"12","author":[{"given":"Pauline","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T.","family":"Crump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan T.C.J.M.","family":"Arentsen-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rico","family":"Hagelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne R.S.","family":"Adriaanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy S.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nierkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Koopmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"issue":"25","key":"445_CR1","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","volume":"37","author":"R Pieters","year":"2019","unstructured":"Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of Infants younger than 1 year with Acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an International Phase III Randomized Study. J Clin Oncol. 2019;37(25):2246\u201356.","journal-title":"J Clin Oncol"},{"issue":"9583","key":"445_CR2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","volume":"370","author":"R Pieters","year":"2007","unstructured":"Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240\u201350.","journal-title":"Lancet"},{"issue":"2","key":"445_CR3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","volume":"32","author":"C Meyer","year":"2018","unstructured":"Meyer C, Burmeister T, Groger D, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32(2):273\u201384.","journal-title":"Leukemia"},{"issue":"4","key":"445_CR4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00062752-200207000-00004","volume":"9","author":"P Ernst","year":"2002","unstructured":"Ernst P, Wang J, Korsmeyer SJ. The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol. 2002;9(4):282\u20137.","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"445_CR5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823\u201333.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"445_CR6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2217\/epi.11.98","volume":"3","author":"KM Bernt","year":"2011","unstructured":"Bernt KM, Armstrong SA. A role for DOT1L in MLL-rearranged leukemias. Epigenomics. 2011;3(6):667\u201370.","journal-title":"Epigenomics"},{"issue":"1","key":"445_CR7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","volume":"20","author":"KM Bernt","year":"2011","unstructured":"Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20(1):66\u201378.","journal-title":"Cancer Cell"},{"issue":"2","key":"445_CR8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","volume":"121","author":"Y Okada","year":"2005","unstructured":"Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005;121(2):167\u201378.","journal-title":"Cell"},{"issue":"5","key":"445_CR9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2008.10.001","volume":"14","author":"AV Krivtsov","year":"2008","unstructured":"Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14(5):355\u201368.","journal-title":"Cancer Cell"},{"issue":"6","key":"445_CR10","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2018.206375","volume":"104","author":"A Agraz-Doblas","year":"2019","unstructured":"Agraz-Doblas A, Bueno C, Bashford-Rogers R, et al. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. Haematologica. 2019;104(6):1176\u201388.","journal-title":"Haematologica"},{"issue":"4","key":"445_CR11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","volume":"47","author":"AK Andersson","year":"2015","unstructured":"Andersson AK, Ma J, Wang J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330\u20137.","journal-title":"Nat Genet"},{"issue":"25","key":"445_CR12","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1182\/blood-2015-09-667378","volume":"126","author":"A Sanjuan-Pla","year":"2015","unstructured":"Sanjuan-Pla A, Bueno C, Prieto C, et al. Revisiting the biology of infant t(4;11)\/MLL-AF4 + B-cell acute lymphoblastic leukemia. Blood. 2015;126(25):2676\u201385.","journal-title":"Blood"},{"issue":"1","key":"445_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","volume":"20","author":"SR Daigle","year":"2011","unstructured":"Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53\u201365.","journal-title":"Cancer Cell"},{"issue":"6","key":"445_CR14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","volume":"122","author":"SR Daigle","year":"2013","unstructured":"Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122(6):1017\u201325.","journal-title":"Blood"},{"issue":"24","key":"445_CR15","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","volume":"131","author":"EM Stein","year":"2018","unstructured":"Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018;131(24):2661\u20139.","journal-title":"Blood"},{"issue":"2","key":"445_CR16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MOH.0000000000000123","volume":"22","author":"EM Stein","year":"2015","unstructured":"Stein EM, Tallman MS. Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L. Curr Opin Hematol. 2015;22(2):92\u20136.","journal-title":"Curr Opin Hematol"},{"issue":"8","key":"445_CR17","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/1535-7163.MCT-16-0693","volume":"16","author":"CT Campbell","year":"2017","unstructured":"Campbell CT, Haladyna JN, Drubin DA, et al. Mechanisms of Pinometostat (EPZ-5676) treatment-emergent resistance in MLL-Rearranged leukemia. Mol Cancer Ther. 2017;16(8):1669\u201379.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"445_CR18","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.2020006113","volume":"136","author":"F Perner","year":"2020","unstructured":"Perner F, Gadrey JY, Xiong Y, et al. Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood. 2020;136(17):1983\u20138.","journal-title":"Blood"},{"issue":"8","key":"445_CR19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1021\/acsmedchemlett.6b00167","volume":"7","author":"C Chen","year":"2016","unstructured":"Chen C, Zhu H, Stauffer F, et al. Discovery of Novel Dot1L inhibitors through a structure-based Fragmentation Approach. ACS Med Chem Lett. 2016;7(8):735\u201340.","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"445_CR20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4161\/cc.27757","volume":"13","author":"MH van der Linden","year":"2014","unstructured":"van der Linden MH, Willekes M, van Roon E, et al. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle. 2014;13(5):834\u201344.","journal-title":"Cell Cycle"},{"issue":"4","key":"445_CR21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2013.245","volume":"28","author":"JA Spijkers-Hagelstein","year":"2014","unstructured":"Spijkers-Hagelstein JA, Pinhancos SS, Schneider P, Pieters R, Stam RW. Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL. Leukemia. 2014;28(4):761\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"445_CR22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.1994.tb04726.x","volume":"86","author":"J Greil","year":"1994","unstructured":"Greil J, Gramatzki M, Burger R, et al. The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br J Haematol. 1994;86(2):275\u201383.","journal-title":"Br J Haematol"},{"issue":"6","key":"445_CR23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s13318-017-0404-3","volume":"42","author":"NJ Waters","year":"2017","unstructured":"Waters NJ. Preclinical pharmacokinetics and pharmacodynamics of Pinometostat (EPZ-5676), a first-in-Class, small molecule S-Adenosyl methionine competitive inhibitor of DOT1L. Eur J Drug Metab Pharmacokinet. 2017;42(6):891\u2013901.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"24","key":"445_CR24","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1101\/gad.1741408","volume":"22","author":"MG Guenther","year":"2008","unstructured":"Guenther MG, Lawton LN, Rozovskaia T, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008;22(24):3403\u20138.","journal-title":"Genes Dev"},{"issue":"2","key":"445_CR25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.celrep.2016.12.054","volume":"18","author":"J Kerry","year":"2017","unstructured":"Kerry J, Godfrey L, Repapi E, et al. MLL-AF4 spreading identifies binding Sites that are distinct from super-enhancers and that govern sensitivity to DOT1L inhibition in Leukemia. Cell Rep. 2017;18(2):482\u201395.","journal-title":"Cell Rep"},{"issue":"3","key":"445_CR26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/1061186X.2018.1479756","volume":"27","author":"A Barzegar Behrooz","year":"2019","unstructured":"Barzegar Behrooz A, Syahir A, Ahmad S. CD133: beyond a cancer stem cell biomarker. J Drug Target. 2019;27(3):257\u201369.","journal-title":"J Drug Target"},{"issue":"8","key":"445_CR27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1089\/scd.2008.0338","volume":"18","author":"Y Wu","year":"2009","unstructured":"Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18(8):1127\u201334.","journal-title":"Stem Cells Dev"},{"issue":"2","key":"445_CR28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2009.08.010","volume":"289","author":"Q Zhang","year":"2010","unstructured":"Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett. 2010;289(2):151\u201360.","journal-title":"Cancer Lett"},{"issue":"1","key":"445_CR29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41375-020-0808-y","volume":"35","author":"L Godfrey","year":"2021","unstructured":"Godfrey L, Crump NT, O\u2019Byrne S, et al. H3K79me2\/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1\/CD133 in MLL-AF4 leukemia cells. Leukemia. 2021;35(1):90\u2013106.","journal-title":"Leukemia"},{"issue":"8","key":"445_CR30","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-11-3589","volume":"72","author":"AB Mak","year":"2012","unstructured":"Mak AB, Nixon AM, Moffat J. The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription. Cancer Res. 2012;72(8):1929\u201334.","journal-title":"Cancer Res"},{"issue":"8","key":"445_CR31","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.leukres.2015.04.012","volume":"39","author":"M Adamaki","year":"2015","unstructured":"Adamaki M, Lambrou GI, Athanasiadou A, Vlahopoulos S, Papavassiliou AG, Moschovi M. HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: significant correlation with relapse and overall survival. Leuk Res. 2015;39(8):874\u201382.","journal-title":"Leuk Res"},{"issue":"18","key":"445_CR32","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1128\/MCB.00545-09","volume":"29","author":"YL Hu","year":"2009","unstructured":"Hu YL, Fong S, Ferrell C, Largman C, Shen WF. HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis. Mol Cell Biol. 2009;29(18):5181\u201392.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"445_CR33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cyto.b.21050","volume":"84","author":"H Dobrowolska","year":"2013","unstructured":"Dobrowolska H, Gill KZ, Serban G, et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytometry B Clin Cytom. 2013;84(1):21\u20139.","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"445_CR34","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1038\/s41598-017-00816-2","volume":"7","author":"AFO Costa","year":"2017","unstructured":"Costa AFO, Menezes DL, Pinheiro LHS, et al. Role of new immunophenotypic markers on prognostic and overall survival of Acute myeloid leukemia: a systematic review and Meta-analysis. Sci Rep. 2017;7(1):4138.","journal-title":"Sci Rep"},{"issue":"4","key":"445_CR35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cyto.b.21952","volume":"100","author":"HRO Churchill","year":"2021","unstructured":"Churchill HRO, Fuda FS, Xu J, et al. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytometry B Clin Cytom. 2021;100(4):476\u201387.","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"445_CR36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0925-5710(94)00348-I","volume":"61","author":"J Hara","year":"1995","unstructured":"Hara J, Hosoi G, Okamura T, et al. CD33 + B-cell precursor acute lymphoblastic leukemia in children: a distinct subgroup of B-cell precursor acute lymphoblastic leukemia. Int J Hematol. 1995;61(2):77\u201384.","journal-title":"Int J Hematol"},{"key":"445_CR37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2021.10.004","volume":"160","author":"J Stutterheim","year":"2022","unstructured":"Stutterheim J, de Lorenzo P, van der Sluis IM, et al. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol. Eur J Cancer. 2022;160:72\u20139.","journal-title":"Eur J Cancer"},{"issue":"6","key":"445_CR38","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.20.02333","volume":"39","author":"J Stutterheim","year":"2021","unstructured":"Stutterheim J, van der Sluis IM, de Lorenzo P, et al. Clinical implications of minimal residual disease detection in infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia treated on the Interfant-06 protocol. J Clin Oncol. 2021;39(6):652\u201362.","journal-title":"J Clin Oncol"},{"issue":"4","key":"445_CR39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","volume":"28","author":"GS Laszlo","year":"2014","unstructured":"Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28(4):143\u201353.","journal-title":"Blood Rev"},{"issue":"9","key":"445_CR40","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/leu.2012.121","volume":"26","author":"JJ van Dongen","year":"2012","unstructured":"van Dongen JJ, Orfao A, EuroFlow C, EuroFlow. Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia. 2012;26(9):1899\u2013907.","journal-title":"Leukemia"},{"issue":"9","key":"445_CR41","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJ van Dongen","year":"2012","unstructured":"van Dongen JJ, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908\u201375.","journal-title":"Leukemia"},{"issue":"9","key":"445_CR42","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986\u20132010.","journal-title":"Leukemia"},{"issue":"3","key":"445_CR43","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s12033-010-9321-2","volume":"46","author":"BC Baguley","year":"2010","unstructured":"Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 2010;46(3):308\u201316.","journal-title":"Mol Biotechnol"},{"issue":"3","key":"445_CR44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szakacs","year":"2006","unstructured":"Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219\u201334.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"445_CR45","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1186\/s12885-022-10221-2","volume":"22","author":"R Dillon","year":"2022","unstructured":"Dillon R, Maycock S, Jackson A, et al. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. BMC Cancer. 2022;22(1):1174.","journal-title":"BMC Cancer"},{"issue":"33","key":"445_CR46","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Reville PK, Wang X, et al. Phase II study of Venetoclax added to Cladribine Plus Low-Dose Cytarabine Alternating with 5-Azacitidine in older patients with newly diagnosed Acute myeloid leukemia. J Clin Oncol. 2022;40(33):3848\u201357.","journal-title":"J Clin Oncol"},{"issue":"15","key":"445_CR47","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax Combined with Low-Dose Cytarabine for previously untreated patients with Acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019;37(15):1277\u201384.","journal-title":"J Clin Oncol"},{"issue":"9","key":"445_CR48","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/cr.2011.115","volume":"21","author":"AT Nguyen","year":"2011","unstructured":"Nguyen AT, He J, Taranova O, Zhang Y. Essential role of DOT1L in maintaining normal adult hematopoiesis. Cell Res. 2011;21(9):1370\u20133.","journal-title":"Cell Res"},{"issue":"5","key":"445_CR49","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.celrep.2015.04.004","volume":"11","author":"A Kuntimaddi","year":"2015","unstructured":"Kuntimaddi A, Achille NJ, Thorpe J, et al. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential. Cell Rep. 2015;11(5):808\u201320.","journal-title":"Cell Rep"},{"issue":"44","key":"445_CR50","doi-asserted-by":"crossref","first-page":"27365","DOI":"10.1073\/pnas.2001075117","volume":"117","author":"K Cao","year":"2020","unstructured":"Cao K, Ugarenko M, Ozark PA, et al. DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation. Proc Natl Acad Sci U S A. 2020;117(44):27365\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"445_CR51","first-page":"27","volume":"118","author":"A Wu","year":"2021","unstructured":"Wu A, Zhi J, Tian T, et al. DOT1L complex regulates transcriptional initiation in human erythroleukemic cells. Proc Natl Acad Sci U S A. 2021;118:27.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"445_CR52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-022-01251-1","volume":"15","author":"Y Yi","year":"2022","unstructured":"Yi Y, Ge S. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. J Hematol Oncol. 2022;15(1):35.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"445_CR53","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-018-0212-z","volume":"32","author":"D Li","year":"2018","unstructured":"Li D, Hu Y, Jin Z, et al. TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells. Leukemia. 2018;32(9):2012\u20136.","journal-title":"Leukemia"},{"issue":"8","key":"445_CR54","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/s41375-019-0418-8","volume":"33","author":"C Bueno","year":"2019","unstructured":"Bueno C, Velasco-Hernandez T, Gutierrez-Aguera F, et al. CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. Leukemia. 2019;33(8):2090\u2013125.","journal-title":"Leukemia"},{"issue":"13","key":"445_CR55","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood.2019001289","volume":"134","author":"S O\u2019Byrne","year":"2019","unstructured":"O\u2019Byrne S, Elliott N, Rice S, et al. Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs. Blood. 2019;134(13):1059\u201371.","journal-title":"Blood"},{"issue":"14","key":"445_CR56","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.2021013442","volume":"139","author":"C Chen","year":"2022","unstructured":"Chen C, Yu W, Alikarami F, et al. Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. Blood. 2022;139(14):2198\u2013211.","journal-title":"Blood"},{"issue":"11","key":"445_CR57","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1158\/1535-7163.MCT-20-0407","volume":"19","author":"Y Anami","year":"2020","unstructured":"Anami Y, Deng M, Gui X, et al. LILRB4-targeting antibody-drug conjugates for the treatment of Acute myeloid leukemia. Mol Cancer Ther. 2020;19(11):2330\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"445_CR58","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/2326-6066.CIR-19-0036","volume":"7","author":"X Gui","year":"2019","unstructured":"Gui X, Deng M, Song H, et al. Disrupting LILRB4\/APOE Interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML Development. Cancer Immunol Res. 2019;7(8):1244\u201357.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"445_CR59","first-page":"16","volume":"4","author":"M Deng","year":"2021","unstructured":"Deng M, Chen H, Liu X, et al. Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer. Antib Ther. 2021;4(1):16\u201333.","journal-title":"Antib Ther"},{"key":"445_CR60","doi-asserted-by":"crossref","unstructured":"Dhunputh C, Strullu M, Petit A et al. Single-dose (4.5\u00a0mg\/m(2)) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia. Br J Haematol. 2022.","DOI":"10.1111\/bjh.18203"},{"issue":"1","key":"445_CR61","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/jcm4010127","volume":"4","author":"JD de Rooij","year":"2015","unstructured":"de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M, Pediatric AML. From Biology to Clinical Management. J Clin Med. 2015;4(1):127\u201349.","journal-title":"J Clin Med"},{"key":"445_CR62","first-page":"419","volume":"15","author":"T Abuasab","year":"2021","unstructured":"Abuasab T, Rowe J, Tvito A. Emerging monoclonal antibody therapy for the treatment of Acute Lymphoblastic Leukemia. Biologics. 2021;15:419\u201331.","journal-title":"Biologics"},{"issue":"18","key":"445_CR63","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1002\/cncr.32354","volume":"125","author":"MM Percival","year":"2019","unstructured":"Percival MM, Estey EH. Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. Cancer. 2019;125(18):3121\u201330.","journal-title":"Cancer"},{"issue":"10","key":"445_CR64","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","volume":"26","author":"S John","year":"2018","unstructured":"John S, Chen H, Deng M, et al. A novel Anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 2018;26(10):2487\u201395.","journal-title":"Mol Ther"},{"key":"445_CR65","doi-asserted-by":"crossref","unstructured":"Smith CHR, Xie J, Liu X, He Y, Ludwig K, Klesse L, Zhang C, John S. LILRB4 is a Novel Target for KMT2A rearranged Acute Leukemia. Blood; 2022.","DOI":"10.1182\/blood-2022-168410"},{"issue":"12","key":"445_CR66","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","volume":"13","author":"JM Benito","year":"2015","unstructured":"Benito JM, Godfrey L, Kojima K, et al. MLL-Rearranged Acute Lymphoblastic Leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-Specific antagonist ABT-199. Cell Rep. 2015;13(12):2715\u201327.","journal-title":"Cell Rep"},{"key":"445_CR67","doi-asserted-by":"crossref","unstructured":"Gibson A, Trabal A, McCall D et al. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel). 2021;14(1).","DOI":"10.3390\/cancers14010150"},{"issue":"10","key":"445_CR68","doi-asserted-by":"crossref","first-page":"e28398","DOI":"10.1002\/pbc.28398","volume":"67","author":"AC Winters","year":"2020","unstructured":"Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatr Blood Cancer. 2020;67(10):e28398.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00445-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-023-00445-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00445-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:09:05Z","timestamp":1700240945000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00445-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["445"],"URL":"https:\/\/doi.org\/10.1186\/s40164-023-00445-8","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.A.M. and N.T.C. are paid consultants for and shareholders in Dark Blue Therapeutics Ltd. The other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"81"}}